23.39% to Target, SunTrust Robinson Reaffirms Buy Rating for Sabra Healthcare REIT (SBRA) Stock; Gamble Jones Investment Counsel Has Trimmed Abbvie (ABBV) Holding By $707,784

Gamble Jones Investment Counsel decreased Abbvie Inc (ABBV) stake by 3.88% reported in 2017Q3 SEC filing. Gamble Jones Investment Counsel sold 8,043 shares as Abbvie Inc (ABBV)’s stock rose 6.17%. The Gamble Jones Investment Counsel holds 199,464 shares with $17.72M value, down from 207,507 last quarter. Abbvie Inc now has $168.87 billion valuation. The stock increased 1.09% or $1.14 during the last trading session, reaching $105.78. About 1.21M shares traded. AbbVie Inc. (NYSE:ABBV) has risen 10.63% since January 22, 2017 and is uptrending. It has underperformed by 6.07% the S&P500.

Among 14 analysts covering Sabra Health Care REIT (NASDAQ:SBRA), 6 have Buy rating, 2 Sell and 6 Hold. Therefore 43% are positive. Sabra Health Care REIT has $32 highest and $20.0 lowest target. $24.17’s average target is 35.56% above currents $17.83 stock price. Sabra Health Care REIT had 45 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, August 6 by Mizuho. Jefferies maintained the stock with “Buy” rating in Monday, September 18 report. The rating was maintained by SunTrust on Thursday, November 2 with “Buy”. The rating was maintained by Cantor Fitzgerald with “Buy” on Wednesday, January 3. Mizuho downgraded Sabra Health Care REIT, Inc. (NASDAQ:SBRA) on Thursday, May 19 to “Neutral” rating. Mizuho maintained it with “Neutral” rating and $28 target in Monday, February 27 report. The firm earned “Underperform” rating on Monday, November 2 by RBC Capital Markets. The firm earned “Neutral” rating on Monday, November 2 by Bank of America. The rating was maintained by Jefferies on Monday, June 12 with “Hold”. The rating was maintained by Barclays Capital with “Overweight” on Wednesday, November 11.

Among 21 analysts covering Abbvie Inc (NYSE:ABBV), 11 have Buy rating, 1 Sell and 9 Hold. Therefore 52% are positive. Abbvie Inc had 71 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Buy” rating by Jefferies given on Monday, December 7. The firm has “Buy” rating given on Monday, March 7 by Goldman Sachs. The rating was maintained by Leerink Swann with “Outperform” on Monday, October 30. The firm earned “Market Perform” rating on Friday, June 10 by BMO Capital Markets. The stock has “Neutral” rating by Citigroup on Monday, November 28. The firm has “Outperform” rating given on Friday, February 5 by William Blair. Barclays Capital downgraded AbbVie Inc. (NYSE:ABBV) on Tuesday, December 1 to “Equal-Weight” rating. As per Friday, October 23, the company rating was maintained by UBS. The firm has “Buy” rating by Jefferies given on Thursday, May 25. On Thursday, January 4 the stock rating was maintained by Jefferies with “Buy”.

Since July 31, 2017, it had 0 insider buys, and 8 selling transactions for $45.57 million activity. 87,040 shares were sold by RICHMOND TIMOTHY J., worth $8.57M. GONZALEZ RICHARD A also sold $13.71 million worth of AbbVie Inc. (NYSE:ABBV) shares. 300 shares valued at $21,127 were sold by Gosebruch Henry O on Monday, July 31. Michael Robert A. also sold $589,512 worth of AbbVie Inc. (NYSE:ABBV) shares. $705,655 worth of AbbVie Inc. (NYSE:ABBV) shares were sold by SALEKI-GERHARDT AZITA. Schumacher Laura J sold 145,510 shares worth $14.07M.

Gamble Jones Investment Counsel increased Vanguard Bd Index Fd Inc (BND) stake by 11,979 shares to 91,407 valued at $7.49M in 2017Q3. It also upped Vanguard World Fds (VPU) stake by 7,718 shares and now owns 14,478 shares. Vanguard Specialized Portfol (VIG) was raised too.

Analysts await AbbVie Inc. (NYSE:ABBV) to report earnings on January, 26. They expect $1.43 EPS, up 19.17% or $0.23 from last year’s $1.2 per share. ABBV’s profit will be $2.28B for 18.49 P/E if the $1.43 EPS becomes a reality. After $1.41 actual EPS reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts 1.42% EPS growth.

Investors sentiment decreased to 0.85 in 2017 Q3. Its down 0.15, from 1 in 2017Q2. It dropped, as 55 investors sold ABBV shares while 640 reduced holdings. 132 funds opened positions while 462 raised stakes. 1.06 billion shares or 1.89% more from 1.04 billion shares in 2017Q2 were reported. Envestnet Asset Incorporated holds 305,089 shares. De Burlo Gp invested in 35,675 shares or 0.7% of the stock. Scotia Capital holds 0.16% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 124,472 shares. M Kraus holds 68,808 shares. Pettee Invsts holds 32,160 shares or 1.85% of its portfolio. Baldwin Brothers Ma stated it has 5,321 shares. Lakeview Partners Limited Liability reported 4,264 shares or 0.3% of all its holdings. Wells Fargo & Mn invested in 13.40M shares. Cubic Asset Ltd Llc reported 45,260 shares or 1.13% of all its holdings. Gulf Interest Bancorporation (Uk), United Kingdom-based fund reported 502,599 shares. Fort Point Capital Prtn Lc holds 4.91% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 115,421 shares. Wharton Business Group invested in 42,475 shares or 0.4% of the stock. Mirador Prns LP holds 1.02% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 19,297 shares. Dnb Asset Management As holds 165,295 shares or 0.2% of its portfolio. Ntv Asset Management Ltd Company reported 0.72% stake.

Sabra Health Care REIT, Inc. operates as a real estate investment trust in the United States. The company has market cap of $3.18 billion. The company, through its subsidiaries, owns and invests in real estate properties for the healthcare industry. It has a 20.49 P/E ratio. The Company’s property portfolio consists of 86 properties comprising 67 skilled nursing facilities; 10 combined skilled nursing, assisted living, and independent living facilities; 5 assisted living facilities; 2 mental health facilities; 1 independent living facility; and 1 continuing care retirement community.

Investors sentiment increased to 5.24 in 2017 Q3. Its up 3.43, from 1.81 in 2017Q2. It is positive, as 26 investors sold Sabra Health Care REIT, Inc. shares while 23 reduced holdings. 133 funds opened positions while 124 raised stakes. 297.15 million shares or 307.35% more from 72.95 million shares in 2017Q2 were reported. Moreover, Eii has 0.36% invested in Sabra Health Care REIT, Inc. (NASDAQ:SBRA). Barclays Public Ltd Liability Co holds 0% of its portfolio in Sabra Health Care REIT, Inc. (NASDAQ:SBRA) for 15,443 shares. The Massachusetts-based Commonwealth Equity has invested 0% in Sabra Health Care REIT, Inc. (NASDAQ:SBRA). Strategic Wealth Advsrs Gp Lc invested in 20,824 shares or 0.07% of the stock. Zebra Cap Management Ltd Liability accumulated 10,341 shares. Northern Trust has 0.02% invested in Sabra Health Care REIT, Inc. (NASDAQ:SBRA). Motco has 44 shares for 0% of their portfolio. Brinker Cap holds 25,758 shares. Employees Retirement Association Of Colorado accumulated 38,379 shares. Oxbow Advsr Limited Company reported 10,068 shares stake. Jnba Advisors reported 220 shares or 0% of all its holdings. Tudor Inv Et Al reported 138,995 shares or 0.08% of all its holdings. Moreover, Jacobus Wealth Mngmt has 0.07% invested in Sabra Health Care REIT, Inc. (NASDAQ:SBRA) for 12,956 shares. Commonwealth Of Pennsylvania Public School Empls Retrmt System, Pennsylvania-based fund reported 25,653 shares. Moody Savings Bank Division reported 22,633 shares.

The stock increased 0.37% or $0.07 during the last trading session, reaching $17.83. About 444,608 shares traded. Sabra Health Care REIT, Inc. (NASDAQ:SBRA) has risen 23.68% since January 22, 2017 and is uptrending. It has outperformed by 6.98% the S&P500.

Analysts await Sabra Health Care REIT, Inc. (NASDAQ:SBRA) to report earnings on February, 28. They expect $0.67 EPS, up 8.06% or $0.05 from last year’s $0.62 per share. SBRA’s profit will be $119.38 million for 6.65 P/E if the $0.67 EPS becomes a reality. After $0.60 actual EPS reported by Sabra Health Care REIT, Inc. for the previous quarter, Wall Street now forecasts 11.67% EPS growth.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: